Amgen quarterly results beat Wall Street estimates

Amgen reported strong second-quarter results, surpassing analyst expectations with revenue up 9% to $9.2 billion and adjusted EPS increasing 21% to $6.02, driven by robust product sales. While cholesterol drug Repatha saw a 31% sales increase, bone drug Prolia experienced a 4% decline due to biosimilar competition, a trend expected to continue. The company slightly raised its full-year adjusted EPS and revenue outlook, and anticipates key mid-stage data in Q4 for its experimental weight-loss drug MariTide, a significant pipeline catalyst.

Analysis

Amgen (AMGN) reported a strong second quarter, exceeding Wall Street expectations with revenue rising 9% year-over-year to $9.2 billion and adjusted earnings per share increasing 21% to $6.02, against consensus estimates of $8.94 billion and $5.29, respectively. This performance was driven by a 9% rise in product sales, highlighted by a 31% sales surge in the cholesterol drug Repatha to $696 million. However, this growth was partially offset by a 4% decline in sales for the bone drug Prolia to $1.1 billion, with the company explicitly warning of further erosion due to emerging biosimilar competition. Operationally, adjusted expenses grew 8%, with a notable 18% increase in R&D costs, reflecting investment in the pipeline. Looking forward, Amgen raised its full-year guidance to an adjusted EPS of $20.20-$21.30 on revenue of $35 billion-$36 billion. The most significant near-term catalyst is the anticipated fourth-quarter data from mid-stage studies of its experimental weight-loss drug, MariTide. The company also flagged external risks, noting that its outlook does not account for potential future tariffs or U.S. drug pricing actions.

Key Decisions for Investors

• The strong Q2 earnings beat and raised full-year guidance support a constructive view on Amgen's near-term operational performance, though the 18% rise in R&D spending should be monitored for its impact on margins.
• The upcoming fourth-quarter data for the experimental weight-loss drug MariTide is a primary catalyst that could significantly influence the stock's valuation and long-term growth trajectory.
• Investors should closely track the impact of biosimilar competition on Prolia sales as a key headwind, while also remaining cognizant of macro risks from potential new tariffs and U.S. drug pricing legislation not factored into current guidance.